CRISPR Therapeutics (CRSP) Says EPO to Grant CRISPR/Cas Gene Editing Patent – StreetInsider.com
McGill Tribune |
CRISPR Therapeutics (CRSP) Says EPO to Grant CRISPR/Cas Gene Editing Patent
StreetInsider.com CRISPR Therapeutics (NASDAQ: CRSP) reported that the European Patent Office (EPO) has announced its intention to grant a patent broadly covering CRISPR's in-licensed gene editing technology. The claims are directed to the CRISPR/Cas9 single-guide … What's the deal with CRISPR? European Patent Office to Grant Broad Claims on Patent Covering … |
